AR124604A1 - Mutantes de fimh, composiciones con los mismos y uso de los mismos - Google Patents

Mutantes de fimh, composiciones con los mismos y uso de los mismos

Info

Publication number
AR124604A1
AR124604A1 ARP220100049A ARP220100049A AR124604A1 AR 124604 A1 AR124604 A1 AR 124604A1 AR P220100049 A ARP220100049 A AR P220100049A AR P220100049 A ARP220100049 A AR P220100049A AR 124604 A1 AR124604 A1 AR 124604A1
Authority
AR
Argentina
Prior art keywords
fimh
lectin domain
compositions
mutants
polypeptides
Prior art date
Application number
ARP220100049A
Other languages
English (en)
Inventor
Jan Grijpstra
Eveline Marleen Weerdenbburg
Jeroen Geurtsen
Kellen Cristhina Fae
Louris Jakob Feitsma
Original Assignee
Janssen Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceuticals Inc filed Critical Janssen Pharmaceuticals Inc
Publication of AR124604A1 publication Critical patent/AR124604A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/025—Enterobacteriales, e.g. Enterobacter
    • A61K39/0258—Escherichia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/24—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
    • C07K14/245—Escherichia (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Urology & Nephrology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

Se describen polipéptidos que comprenden un dominio de lectina de FimH que comprenden al menos una mutación de aminoácidos que hace que el dominio de lectina de FimH esté en la conformación de baja afinidad por manosa. Se describen adicionalmente composiciones farmacéuticas que comprenden dichos polipéptidos y métodos para estimular una respuesta inmunitaria en un sujeto que lo necesita mediante la administración del polipéptido. Reivindicación 1: Un polipéptido que comprende un dominio de lectina de FimH que comprende Tirosina (Y) o Triptófano (W) en la posición que corresponde a la posición 71 en la SEQ ID Nº 1.
ARP220100049A 2021-01-12 2022-01-11 Mutantes de fimh, composiciones con los mismos y uso de los mismos AR124604A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP21151126 2021-01-12

Publications (1)

Publication Number Publication Date
AR124604A1 true AR124604A1 (es) 2023-04-12

Family

ID=74175646

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP220100049A AR124604A1 (es) 2021-01-12 2022-01-11 Mutantes de fimh, composiciones con los mismos y uso de los mismos

Country Status (11)

Country Link
US (2) US11725028B2 (es)
EP (1) EP4277921A1 (es)
JP (1) JP2024502854A (es)
KR (1) KR20230125842A (es)
CN (1) CN116888140A (es)
AR (1) AR124604A1 (es)
CA (1) CA3207841A1 (es)
IL (1) IL303954A (es)
MX (1) MX2023008251A (es)
TW (1) TW202241929A (es)
WO (1) WO2022153166A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023111907A1 (en) * 2021-12-17 2023-06-22 Pfizer Inc. Polynucleotide compositions and uses thereof

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4436727A (en) 1982-05-26 1984-03-13 Ribi Immunochem Research, Inc. Refined detoxified endotoxin product
US4866034A (en) 1982-05-26 1989-09-12 Ribi Immunochem Research Inc. Refined detoxified endotoxin
US4987237A (en) 1983-08-26 1991-01-22 Ribi Immunochem Research, Inc. Derivatives of monophosphoryl lipid A
US4877611A (en) 1986-04-15 1989-10-31 Ribi Immunochem Research Inc. Vaccine containing tumor antigens and adjuvants
US5057540A (en) 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
US4912094B1 (en) 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
JPH0832638B2 (ja) 1989-05-25 1996-03-29 カイロン コーポレイション サブミクロン油滴乳剤を含んで成るアジュバント製剤
JPH0655749B2 (ja) 1989-09-20 1994-07-27 日本たばこ産業株式会社 リピッドａ単糖類縁体
US5370872A (en) 1991-08-12 1994-12-06 Swiss Serum And Vaccine Institute Berne Escherichia coliO-polysaccharide-protein conjugate vaccine
US5593969A (en) 1991-09-03 1997-01-14 Igen Incorporated Lipid-A analogs: monosaccharide and dissaccharide compounds for inhibiting binding of lipid A receptors to lipid A receptors
PT761231E (pt) 1992-06-25 2000-06-30 Smithkline Beecham Biolog Composicao de vacina contendo adjuvantes
UA56132C2 (uk) 1995-04-25 2003-05-15 Смітклайн Бічем Байолоджікалс С.А. Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини
US6491919B2 (en) 1997-04-01 2002-12-10 Corixa Corporation Aqueous immunologic adjuvant compostions of monophosphoryl lipid A
NZ338101A (en) 1997-04-01 2002-03-28 Corixa Corp Adjuvant compositions of Monophosphoryl Lipid A (MPL) and a phospholipid based surfactant (1,2-Dipalmitoyl-sn-glycero-3-phosphocholine (DPPC)) suitable for intranasal administration
US6500434B1 (en) 1998-04-23 2002-12-31 Medimmune, Inc. Chaperone and adhesin proteins; vaccines, diagnostics and method for treating infections
US6858211B1 (en) 1998-07-20 2005-02-22 The United States Of America As Represented By The Department Of Health And Human Services Vaccines against Escherichia coli O157 infection
DE69935606T9 (de) 1998-10-16 2021-03-11 Glaxosmithkline Biologicals S.A. Adjuvanzsysteme und impfstoffe
WO2001005978A1 (en) * 1999-07-15 2001-01-25 Medimmune, Inc. FimH ADHESIN-BASED VACCINES
AU1431101A (en) 1999-10-04 2001-05-10 University Of Maryland Biotechnology Institute Novel adjuvant comprising a lipopolysaccharide antagonist
DE60134499D1 (de) 2000-04-13 2008-07-31 Corixa Corp Immunostimulierende zusammnensetzungen die aminoalkyl glucosaminidephosphat und qs-21 enthalten
CA2414460A1 (en) 2000-07-07 2002-01-17 Medimmune, Inc. Fimh adhesin proteins and methods of use
WO2002015928A1 (en) * 2000-08-18 2002-02-28 Medimmune, Inc. METHOD OF ADMINISTERING FimH PROTEIN AS A VACCINE FOR URINARY TRACT INFECTIONS
AU2001297896A1 (en) * 2000-12-08 2003-01-02 Medimmune, Inc. Mutant proteins, high potency inhibitory antibodies and fimch crystal structure
US6676958B2 (en) 2001-06-19 2004-01-13 Advanced Bioadjuvants, Llc Adjuvant composition for mucosal and injection delivered vaccines
CN101019123A (zh) * 2004-02-06 2007-08-15 科学与工业研究委员会 用于识别有治疗潜力的粘附素和粘附素样蛋白的计算方法
CA2605749C (en) 2005-04-26 2015-06-30 Eisai Co., Ltd. Compositions and methods for cancer immunotherapy
PT2311972E (pt) 2005-05-11 2015-05-13 Eth Zuerich Proteínas n-glicosiladas recombinantes de células procarióticas
TWI457133B (zh) 2005-12-13 2014-10-21 Glaxosmithkline Biolog Sa 新穎組合物
ATE539079T1 (de) 2006-03-23 2012-01-15 Novartis Ag Imidazochinoxalinverbindungen als immunmodulatoren
EP2007765B1 (en) 2006-03-23 2012-06-27 Novartis AG Immunopotentiating compounds
CA2716187C (en) 2008-02-20 2020-01-07 Glycovaxyn Ag Bioconjugates made from recombinant n-glycosylated proteins from procaryotic cells
US8722064B2 (en) 2009-06-05 2014-05-13 Infectious Disease Research Institute Synthetic glucopyranosyl lipid adjuvants
PL2811981T3 (pl) 2012-02-07 2019-09-30 Infectious Disease Research Institute Ulepszone formulacje adiuwantowe zawierające agonistę TLR4 oraz sposoby ich zastosowania
AU2014268836B2 (en) 2013-05-18 2018-08-02 Aduro Biotech, Inc. Compositions and methods for activating "stimulator of interferon gene"-dependent signalling
US9017698B2 (en) 2013-09-25 2015-04-28 Sequoia Sciences, Inc. Compositions of vaccines and adjuvants and methods for the treatment of urinary tract infections
US9415101B2 (en) 2013-09-25 2016-08-16 Sequoia Sciences, Inc. Compositions of vaccines and adjuvants and methods for the treatment of urinary tract infections
US9149522B2 (en) 2013-09-25 2015-10-06 Sequoia Sciences, Inc. Compositions of vaccines and adjuvants and methods for the treatment of urinary tract infections
US9149521B2 (en) 2013-09-25 2015-10-06 Sequoia Sciences, Inc. Compositions of vaccines and adjuvants and methods for the treatment of urinary tract infections
US9504743B2 (en) 2013-09-25 2016-11-29 Sequoia Sciences, Inc Compositions of vaccines and adjuvants and methods for the treatment of urinary tract infections
US9415097B2 (en) 2013-09-25 2016-08-16 Sequoia Sciences, Inc. Compositions of vaccines and adjuvants and methods for the treatment of urinary tract infections
SG11201606889PA (en) 2014-02-24 2016-09-29 Glycovaxyn Ag Novel polysaccharide and uses thereof
EP3693379A1 (en) * 2015-05-13 2020-08-12 University of Washington Compositions and methods for treatment and prevention of uropathogenice. coli
CN116059336A (zh) 2015-07-07 2023-05-05 扬森疫苗与预防公司 针对rsv的疫苗
TWI715617B (zh) 2015-08-24 2021-01-11 比利時商葛蘭素史密斯克藍生物品公司 對抗腸道外病原性大腸桿菌之免疫保護之方法及組合物
JP2020534261A (ja) * 2017-09-08 2020-11-26 ザ ユニバーシティ オブ ブリストル 膜へのタンパク質送達
WO2019175145A1 (en) 2018-03-12 2019-09-19 Janssen Vaccines & Prevention B.V. Vaccines against urinary tract infections
WO2021123360A1 (en) * 2019-12-20 2021-06-24 Vib Vzw Nanobody exchange chromatography
IL294445B2 (en) * 2020-01-16 2023-10-01 Janssen Pharmaceuticals Inc FIMH mutant, its preparations and their use

Also Published As

Publication number Publication date
AU2022207740A1 (en) 2023-06-29
IL303954A (en) 2023-08-01
US11725028B2 (en) 2023-08-15
JP2024502854A (ja) 2024-01-23
US20230406890A1 (en) 2023-12-21
US20220220159A1 (en) 2022-07-14
WO2022153166A1 (en) 2022-07-21
TW202241929A (zh) 2022-11-01
CA3207841A1 (en) 2022-07-21
KR20230125842A (ko) 2023-08-29
EP4277921A1 (en) 2023-11-22
MX2023008251A (es) 2023-07-26
CN116888140A (zh) 2023-10-13

Similar Documents

Publication Publication Date Title
AR121066A1 (es) Mutante de fimh, composiciones que lo contienen y uso del mismo
AR114445A1 (es) Conjugados de il-15, y sus usos
PE20190352A1 (es) Proteinas de fusion gdf 15 y usos de estas
PE20231648A1 (es) CONJUGADOS DE INTERLEUCINA 2 HUMANA SESGADOS AL DIMERO DEL RECEPTOR DE INTERLEUCINA 2 byc Y CONJUGADOS CON UN POLIMERO HIDROSOLUBLE NO PEPTIDICO
AR124604A1 (es) Mutantes de fimh, composiciones con los mismos y uso de los mismos
AR091866A1 (es) Analogos del glucagon
ES2103295T3 (es) Secuencia nucleotida codificante para una proteina de la membrana externa de neisseria meningitidis, y su utilizacion en la preparacion de vacunas.
PE20212265A1 (es) Bioconjugados de antigenos-polisacaridos de e. coli, metodos de produccion y metodos de utilizacion de los mismos
BR112021016728A2 (pt) Bactérias imunostimulatórias projetadas para colonizar tumores, residentes em tumores células imunológicas e o microambiente tumoral
BRPI0415315A (pt) métodos de aumentar uma resposta imune a um antìgeno em um mamìfero, e de reduzir a severidade de um cáncer em um paciente, preparação combinada, kit farmacêutico, e, usos de um polipeptìdeo de il-18 ou seu fragmento ou derivado bioativos, e de uma composição imunogênica
BR112018075785A2 (pt) formulação de vacina para o hiv
CL2022000774A1 (es) Vacunas para vhb y métodos de tratamiento de vhb
BR112013013548B8 (pt) Proteína de fusão anticancerígena
BR112022013795A2 (pt) Composição farmacêutica líquida, e, kit
MA45172B1 (fr) Arn modifié codant pour des polypeptides vegf-a, formulations et utilisations associées
DE602005005449D1 (de) Adjuvante zusammensetzungen
ECSP20067968A (es) Conjugados del péptido de fusión péptido similar al glucagón 1 (glp-1) acoplado al péptido tirosina tirosina cíclico y usos de estos
PE20200514A1 (es) Compuestos de mic-1 y usos de estos
AR102890A1 (es) Polipéptidos que comprenden una secuencia de aminoácidos g3p de bacteriófago sin señal de glucosilación
ATE402956T1 (de) Neue, mhc klasse ii assoziierte peptide
CO2023000307A2 (es) Polipéptidos de mybpc3 y usos de los mismos
BR112023004819A2 (pt) Composições de vacinas multivalentes e seus usos
BR112020004935A2 (pt) Composição farmacêutica compreendendo um anticorpo que se liga especificamente a n-terminal de lisil-trna sintetase como princípio ativo para prevenção ou tratamento de doença relacionada com migração celular
PE20221271A1 (es) Moleculas de fusion del ecd de siglec-9 y metodos de uso de estas
MY197491A (en) Identification of mutations in channelopsin variants having improved light sensitivity and methods of use thereof